Ionis Pharmaceuticals, Inc. announced that the U.S. FDA has approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. The approval was based on Phase 3 CORE and CORE2 studies, which showed TRYNGOLZA demonstrated rapid and consistent triglyceride control, lowering fasting triglyceride levels by up to 72% compared to placebo at six months and sustaining those reductions at 12 months. TRYNGOLZA is available in 50 mg or 80 mg monthly self-administered autoinjector doses. Ionis Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for genetic diseases.
